Page 182 - HIV/AIDS Guidelines

References

1. O'Brien ME, Clark RA, Besch CL, et al. Patterns and correlates of discontinuation of the initial HAART regimen in an
urban outpatient cohort. J Acquir Immune Defic Syndr. 2003;34(4):407-414.

2. Keiser O, Fellay J, Opravil M, et al. Adverse events to antiretrovirals in the Swiss HIV Cohort Study: effect on mortality
and treatment modification. Antivir Ther. 2007;12(8):1157-1164.

3. Baylor MS, Johann-Liang R. Hepatotoxicity associated with nevirapine use. J Acquir Immune Defic Syndr.
2004;35(5):538-539.

4. Bersoff-Matcha SJ, Miller WC, Aberg JA, et al. Sex differences in nevirapine rash. Clin Infect Dis. 2001;32(1):124-129.
5. Fagot JP, Mockenhaupt M, Bouwes-Bavinck J-N, for the EuroSCAR study group. Nevirapine and the risk of Stevens-
Johnson syndrome or toxic epidermal necrolysis. AIDS. 2001;15(14):1843-1848.

6. Moyle GJ, Datta D, Mandalia S, et al. Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance,
reproducibility and possible risk factors. AIDS. 2002;16(10):1341-1349.

7. Bolhaar MG, Karstaedt AS. A high incidence of lactic acidosis and symptomatic hyperlactatemia in women receiving
highly active antiretroviral therapy in Soweto, South Africa. Clin Infect Dis. 2007;45(2):254-260.

8. Geddes R, Knight S, Moosa MY, Reddi A, Uebel K, H S. A high incidence of nucleoside reverse transcriptase inhibitor
(NRTI)-induced lactic acidosis in HIV-infected patients in a South African context. S Afr Med J. 2006;96(8):722-724.

9. Dieterich DT, Robinson PA, Love J, Stern JO. Drug-induced liver injury associated with the use of nonnucleoside
reverse-transcriptase inhibitors. Clin Infect Dis. 2004;38(Suppl 2):S80-89.
10. denBrinker M, Wit FW, Wertheim-van Dillen PM, et al. Hepatitis B and C virus co-infection and the risk for
hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS. 2000;14(18):2895-2902.
11. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults
infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000;283(1):74-80.
12. Saves M, Raffi F, Clevenbergh P, et al. and the APROCO Study Group. Hepatitis B or hepatitis C virus infection is a risk
factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human
immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2000;44(12):3451-3455.
13. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med.
2008;358(6):568-579.
14. Saag M, Balu R, Phillips E, et al. High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically
confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis. 2008;46(7):1111-1118.
15. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med.
Nov 30 2006;355(22):2283-2296.
3
16. Lichtenstein KA, Armon C, Buchacz K, et al. Initiation of antiretroviral therapy at CD4 cell counts ≥350 cells/mm does
not increase incidence or risk of peripheral neuropathy, anemia, or renal insufficiency. J Acquir Immune Defic Syndr. Jan
1 2008;47(1):27-35.
17. European AIDS Clinical Society. Prevention and Management of Non-Infectious Co-Morbidities in HIV. November 1,
2009; http://www.europeanaidsclinicalsociety.org/guidelinespdf/2_Non_Infectious_Co_Morbidities_in_HIV.pdf.
18. Wohl DA, McComsey G, Tebas P, et al. Current concepts in the diagnosis and management of metabolic complications
of HIV infection and its therapy. Clin Infect Dis. Sep 1 2006;43(5):645-653.
19. Dube MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human
immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical
Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. Sep
1 2003;37(5):613-627.

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents K-12

Downloaded from http://aidsinfo.nih.gov/guidelines on 12/8/2012 EST.